EZH2 and prostate cancer: Notably, we demonstrated that the pharmacological inhibition of the histone methyltransferase (HMT) enhancer of zeste 2 polycomb repressive complex 2 (EZH2) using the chemical compound 3-deazaneplanocin A (DZNeP) resulted in the sensitization of radioresistant prostate cancer cells and reduced tumorigenicity [18,19].